TCW Relative Value Mid Cap Fund Exits Teva Position After Valuation Targets Met

TCW Funds reported that the TCW Relative Value Mid Cap Fund sold its entire position in Teva Pharmaceutical Industries Limited (NYSE: TEVA) during the second quarter of 2026. The investment management firm stated that the stock appreciation caused the shares to no longer satisfy the strategy's five valuation characteristics.

The fund's Q2 2026 investor letter attributed the exit to the successful execution of Teva's "Pivot to Branded Growth" strategy, which was launched in May 2023. According to TCW, Teva shifted its product mix away from low-margin generics toward branded and innovative medicines, a move that improved margins and earnings quality. Key drugs including Austedo, Ajovy, and Uzedy delivered significant growth rates, supporting the financial transformation.

Teva also repaired its balance sheet by meaningfully reducing debt, leading to credit rating upgrades from S&P, Moody's, and Fitch. The company resolved legacy opioid litigation and underwent cost restructuring that highlighted cost discipline. Additionally, TCW noted that the Inflation Reduction Act and Medicare price negotiations for Austedo were less severe than investors feared, removing a significant overhang on the stock.

The fund described Teva's evolution from a company burdened by legal issues and debt to a higher-margin, innovation-led biopharmaceutical player. Management's consistent performance against targets provided a more predictable growth profile, while high-profile clinical successes led the market to assign greater value to Teva's internal research and development engine.

At the close on September 30, 2026, Teva shares stood at $39.60, reflecting a market capitalization of $46.19 billion. The stock posted a year-to-date gain of approximately 26.88%, trading within a 52-week range of $18.83 to $40.79. TCW reported that the fund returned 14.10% for the quarter, compared to the S&P 500's 13.40% return.

Database records indicate that 54 hedge fund portfolios held Teva at the end of the second quarter of 2026, an increase from 52 portfolios in the previous quarter. The source noted that while Teva offers growth potential through its $125 million acquisition bid for BioXcel, investors should monitor upcoming FDA decisions and court auction uncertainties.